Skip to main content
Journal cover image

MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study

Publication ,  Conference
Lawitz, E; Bashir, M; Shim-Lopez, J; Lee, J; Song, K; Chen, H; Harrison, S
Published in: JOURNAL OF HEPATOLOGY
2020

Duke Scholars

Published In

JOURNAL OF HEPATOLOGY

EISSN

1600-0641

ISSN

0168-8278

Publication Date

2020

Volume

73

Start / End Page

S132 / S132

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Lawitz, E., Bashir, M., Shim-Lopez, J., Lee, J., Song, K., Chen, H., & Harrison, S. (2020). MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study. In JOURNAL OF HEPATOLOGY (Vol. 73, pp. S132–S132).
Lawitz, Eric, Mustafa Bashir, Jennifer Shim-Lopez, Jonathan Lee, Ken Song, Hubert Chen, and Stephen Harrison. “MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study.” In JOURNAL OF HEPATOLOGY, 73:S132–S132, 2020.
Journal cover image

Published In

JOURNAL OF HEPATOLOGY

EISSN

1600-0641

ISSN

0168-8278

Publication Date

2020

Volume

73

Start / End Page

S132 / S132

Related Subject Headings

  • Gastroenterology & Hepatology
  • 3202 Clinical sciences
  • 1117 Public Health and Health Services
  • 1103 Clinical Sciences